Nanjing Aide Chengningxin Pharmaceutical Research and Development

Nanjing Aide Chengningxin Pharmaceutical Research and Development is a Chinese biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company specializes in multi-agonist treatments targeting the GLP-1, GIP, and glucagon receptors to address conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). By leveraging its expertise in medicinal chemistry, Aide Chengningxin aims to develop oral alternatives to injectable peptide therapies. The firm operates primarily within the Nanjing Jiangbei New Area biopharmaceutical cluster.